Iodine-131 metaiodobenzylguanidine (I-131 MIBG)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-IODINE-131-MIBG |
|---|---|
| Type | Drug |
| Aliases | 131I-MIBGIodine-131 MIBG (iobenguane I 131)iobenguane I-131radioiodinated MIBG therapyЙод-131 метайодбензилгуанідин (I-131 MIBG) |
| Status | pending_clinical_signoff |
| Diseases | DIS-PHEOCHROMOCYTOMA |
| Sources | SRC-NCCN-NET-2025 |
Drug Facts
| Class | Norepinephrine-analogue radiopharmaceutical (beta-emitter) |
|---|---|
| Mechanism | Metaiodobenzylguanidine (MIBG) is a norepinephrine analogue taken up by the noradrenaline transporter (NET/SLC6A2) expressed on catecholamine-secreting neuroendocrine cells, concentrating selectively in pheochromocytoma / paraganglioma (PPGL) tissue when labeled with the beta-emitting radionuclide iodine-131. Tumor selection requires a positive diagnostic MIBG scan (I-123 or I-131 scintigraphy) confirming MIBG avidity before therapeutic administration -- disease that is MIBG-non-avid does not benefit from this modality and is instead routed to systemic TKI therapy (sunitinib / cabozantinib) per ALGO-PHEO-1L. |
| Typical dosing | Weight-based / patient-specific therapeutic activity administered intravenously in a specialized nuclear-medicine facility with radiation-safety isolation, following pre-therapy dosimetry and a confirmatory diagnostic MIBG scan; may be given as staged therapeutic administrations. Exact activity-per-kg, dose-fractionation schedule, and inter-dose interval are governed by patient-specific dosimetry and current product labeling and are deliberately NOT stated as fixed numbers in this stub -- the drafting agent is not confident enough in its recollection of the precise licensed dosing regimen to assert it as fact; a maintainer with access to the current product label should populate this field... |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-07-11 |
Notes
Radiopharmaceutical option for metastatic/unresectable, MIBG-avid pheochromocytoma or paraganglioma, mirroring how other beta/alpha- emitting radiopharmaceuticals (DRUG-RADIUM-223, DRUG-LUTETIUM-177-PSMA) are modelled in this KB. MIBG avidity on diagnostic scintigraphy is a prerequisite for this therapy; MIBG-non-avid disease is not a candidate and follows the systemic-therapy track instead (see ALGO-PHEO-1L). Requires thyroid blockade (potassium iodide/iodate) around administration to protect the thyroid from free radioiodine. An FDA-approved product (iobenguane I-131, brand Azedra) exists for this indication, but the drafting agent did not independently verify its precise licensed activity/kg dosing regimen this session -- precise numbers are deliberately left unstated pending maintainer verification against current product labeling. STUB pending clinical co-lead signoff (CHARTER §6.1, dev-mode-exempted).
Used By
Regimens
REG-IODINE-131-MIBG-PHEO- I-131 MIBG radiopharmaceutical therapy (MIBG-avid metastatic pheochromocytoma/paraganglio...